The mTOR pathway: A new target in cancer therapy

L. Ciuffreda, C. Di Sanza, U. C. Incani, M. Milella

Research output: Contribution to journalArticlepeer-review

Abstract

Mammalian target of rapamycin (mTOR) is a key protein kinase controlling signal transduction from various growth factors and upstream proteins to the level of mRNA translation and ribosome biogenesis, with pivotal regulatory effects on cell cycle progression, cellular proliferation and growth, autophagy and angiogenesis. The mTOR pathway, and its upstream regulators in the PI3K/PTEN/AKT cascade, are altered in a variety of experimental and human malignancies.This has led to the prediction that mTOR inhibitors may be used as anticancer agents. With the recent approval of two mTOR-targeted drugs (temsirolimus and everolimus) for the treatment of renal cell carcinoma and mantle cell lymphoma, this paradigm has been effectively translated into the clinical setting. In this review, we discuss mTOR biology and regulation, the mode of action of mTOR inhibitors as anti-cancer agents, and current clinical evidence supporting the use of rapamycin-like mTOR inhibitors in cancer treatment.

Original languageEnglish
Pages (from-to)484-495
Number of pages12
JournalCurrent Cancer Drug Targets
Volume10
Issue number5
DOIs
Publication statusPublished - 2010

Keywords

  • Angiogenesis
  • Cancer therapy
  • Growth inhibition
  • mTOR
  • Rapamycin-like agents
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The mTOR pathway: A new target in cancer therapy'. Together they form a unique fingerprint.

Cite this